Perioperative Hyper-coagulation and Thrombosis: Cost Analysis After Congenital Heart Surgery

Prior research has shown that Congenital Heart Disease (CHD) patients face significant risks of vascular complications following complex surgical interventions that require cardiopulmonary bypass or extensive tissue reconstruction. These major adverse events frequently correlate with diminished clinical outcomes, increased mortality rates, and significantly higher resource utilization within specialized pediatric intensive care environments. Medical literature suggests that elevated fibrinogen levels might interact with pro-coagulant therapies to exacerbate clotting risks during the acute recovery phase after cardiac repair. While clinicians recognize the inherent danger of clot formation, the specific economic impact and the role of hyperfibrinogenemia in this population remain insufficiently characterized. Understanding the interplay between baseline physiological states and perioperative interventions is necessary to refine current management protocols for children with structural heart defects. This gap motivated the current investigation into how perioperative factors influence both physiological stability and hospital expenditures in the context of high fibrinogen levels.

Researchers examined whether increased administration of pro-coagulant products correlates with postoperative clotting events in patients exhibiting hyperfibrinogenemia following complex surgical procedures for structural heart defects. The investigative team sought to determine if these thrombotic complications directly escalate hospital expenses and blood product requirements during the acute recovery phase. Identifying specific predictors for clot formation served as a primary objective to improve risk stratification protocols and enhance the safety of perioperative blood management. The analysis also focused on quantifying the relationship between single ventricle physiology and adverse vascular outcomes to better understand the risks inherent to specific cardiac anatomies. By evaluating these variables, the authors intended to provide a framework for reducing the financial and clinical burden of pediatric cardiac care through targeted intervention. The study aimed to validate the hypothesis that hypercoagulability and pro-coagulant use synergistically increase the likelihood of expensive and dangerous thrombotic events.

Investigators conducted a single-center retrospective analysis utilizing the electronic health record (EHR) database at Boston Children's Hospital to identify trends in postoperative recovery. The study population included all individuals undergoing surgical repair for structural cardiac defects between 2015 and 2018 who met specific biochemical criteria for inclusion. Inclusion criteria required patients to demonstrate postoperative fibrinogen concentrations exceeding 400 mg/dl during their recovery period to ensure a focus on hyperfibrinogenemic states. Analysts reviewed clinical records for 334 subjects to identify those who developed documented vascular obstructions or other thrombotic complications during their hospital stay. Statistical models utilized odds ratios (OR) and 95% confidence intervals (CI) to evaluate the strength of various predictors for these adverse clinical events. The research team specifically scrutinized baseline hypercoagulability through a comprehensive panel of diagnostic tests to establish a clear physiological starting point for each patient.

Postoperative thrombosis occurred in 8.4% of the cohort, affecting 28 out of 334 patients who exhibited elevated fibrinogen levels following their cardiac surgical procedures. These clotting events were significantly associated with increased hospital expenditures and higher blood product costs compared to patients who did not experience vascular obstructions. Affected children required extended durations of mechanical ventilation and longer intensive care stays relative to those without thrombotic complications, which further escalated total resource consumption. A preoperative hypercoagulable state emerged as a strong predictor of clot formation, yielding an odds ratio of 2.58 with a statistically significant p-value of 0.002. Patients with single ventricle physiology faced a nearly threefold increase in risk, demonstrated by a univariate odds ratio of 2.94 compared to those with other cardiac structures. Analysis identified both preoperative hypercoagulability and intraoperative platelet administration as primary drivers of total institutional costs compared to patients without these specific risk factors.

Vascular complications following pediatric cardiac repair represent a substantial burden on both patient health and healthcare systems, necessitating more precise management of coagulation parameters. The findings emphasize that identifying high-risk individuals before surgery could mitigate the financial impact of postoperative care by allowing for earlier and more targeted interventions. Clinicians should consider the predictive value of preoperative coagulation profiles and the impact of blood product administration when managing patients with complex cardiac anatomies. Future efforts must focus on developing robust risk prediction models to guide targeted thrombosis prevention strategies and improve the overall safety of congenital heart surgery. Improving these predictive capabilities remains necessary for optimizing recovery trajectories and reducing resource consumption in specialized surgical units that handle high-acuity pediatric cases. The study highlights the necessity of balancing pro-coagulant use with the inherent risks of hyperfibrinogenemia to prevent costly and life-threatening thrombotic events in this population.